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Abstract
Impairment of the protein C pathway plays a central role in the
pathogenesis of sepsis. Treatment with recombinant human
activated protein C (rhAPC) has been reported to increase survival
from severe sepsis. Protein C levels also decrease markedly in
acute lung injury, of both septic and nonseptic origin. Low levels of
protein C in acute lung injury are associated with poor clinical
outcome. The present article discusses the beneficial effects of
rhAPC in oleic acid-induced lung injury as well as the controversies
between different animal models and the timing of drug
administration. The unique bronchial circulation in ovine models
seems to be responsible for the beneficial effects of rhAPC when
given simultaneously to the injury.
In the previous issue of Critical Care we read with great
interest a report of the first experimental study of recombinant
human activated protein C (rhAPC) in oleic acid-induced
nonseptic acute lung injury (ALI) in sheep [1].
Impairment of the protein C pathway plays a central role in
the pathogenesis of sepsis. Treatment with rhAPC has been
reported to increase survival from severe sepsis [2]. The
administration of rhAPC may correct the dysregulated anti-
coagulant mechanism and prevent propagation of thrombin
generation and the formation of microvascular thrombosis.
Furthermore, rhAPC may simultaneously modulate the inflam-
matory response. It is likely that the beneficial effects of
rhAPC observed in experimental and clinical studies of
severe sepsis result from a combination of mechanisms that
modulate the interdependent processes of coagulation and
inflammation [3]. Protein C levels also decrease markedly in
ALI, of both septic and nonseptic origin. Low levels of protein
C in ALI are associated with poor clinical outcome [4,5].
In the present study, the authors of the well known group of
Lars Bjertnaes (Tromsø, Norway) showed that simultaneous
administration of rhAPC ameliorates oleic acid-induced (non-
septic) lung injury. The rise in pulmonary artery pressure, the
development of pulmonary edema and the derangement of
arterial oxygenation subsequent to intravenous bolus infusion
of oleic acid all improved significantly during coadministration
of rhAPC [1]. These results are surprising, given the timing of
rhAPC administration.
We recently reviewed studies of rhAPC treatment in sepsis-
related ALI and found the timing of drug administration to be
critical in these experiments [6]. When given prior to the
injury in a porcine model [7] or given simultaneously in
Pseudomonas aeruginosa-induced lung injury in rats [8], the
oxygenation further deteriorated – beneficial effects could
only be shown when rhAPC was given post injury in various
ovine models [9-11]. We hypothesized that rhAPC in the
early stage of ALI may disturb the complex coagulation
balance at the alveolar level, and may impede an initially
positive effect of coagulation activation, because in the early
phase of ALI the epithelial side as well as the endothelial side
of the capillary barrier are involved with fibrin deposition,
reflecting a shift in the alveolar/fibrinolysis balance [6].
The beneficial effects of the simultaneous treatment in the
present study [1], however, are in contrast to our hypothesis
and lead away from the coagulation cascade to the activity of
neutrophils in ALI. During inflammation, activated neutrophils
accumulate in the lungs and other organs, thus contributing
to organ system dysfunction. Neutrophils express receptors
for rhAPC and neutrophil chemotaxis is inhibited by exposure
to rhAPC, explaining its beneficial effects [12].
Our group uses an ovine model of smoke inhalation and
sepsis to induce ALI [13], since smoke inhalation and sepsis
are major contributors to mortality in burn patients [14]. The
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lungs of sheep have a special feature, a single bronchial
artery, and a single lymphatic draining of the lung. A 10-fold
increase in bronchial blood flow could be shown within
20 minutes of smoke inhalation. These same animals demon-
strate a six-fold increase in pulmonary transvascular fluid flux
[13]. The venous outflow of the bronchial circulation drains
into the pulmonary microcirculation at the precapillary level.
Considering the fact that initial damage to the airway
appeared to drive the pathophysiology of the parenchyma,
investigators hypothesized that the bronchial blood might
deliver cytotoxic materials or cells into the pulmonary micro-
circulation. To test this hypothesis, several investigators have
tied off the bronchial artery of sheep and then exposed the
animals to smoke. In these studies the hypothesis was affirmed,
and the lung parenchymal changes were reduced [15].
What could be the linkage between the airway, the bronchial
venous drainage and parenchymal injury to the lung?
Neutrophils activated in the bronchial circulation flow out into
the bronchial venous drainage. Normally, the large neutrophil
can traverse the pulmonary capillary by changing shape.
Many of the neutrophils, however, have been activated in the
bronchial areas – their F-actin is activated and the cells are
stiff and cannot deform. These stiff cells are carried to the
pulmonary microvasculature, where they are impaled by the
narrow pulmonary capillaries. The activated neutrophils
release reactive oxygen species and proteases that damage
the parenchyma [15]. The final proof of this hypothesis was to
deplete the animals of their neutrophils and determine how
this affected the response to inhalation injury. In these studies
of sheep depleted of their leukocytes, a high percentage of
the response to smoke inhalation was blocked [16].
Neutrophils express receptors for rhAPC and neutrophil
chemotaxis is inhibited by exposure to rhAPC [12]. When
rhAPC binds to these receptors, before the cells are drained
via the bronchial venous system into the pulmonary micro-
vasculature, a reduction of ALI may be anticipated. Taking
these facts together, the results of Waerhaug and colleagues
appear in a different light [1]; of course oleic acid-induced
ALI is different from smoke inhalation, but, given the direct
injury to the lung and the fact that sheep have the single
bronchial artery [13], the beneficial effects of a simultaneous
treatment with rhAPC might be more advantageous than in
other models – especially since only sheep subjected to
peritoneal sepsis or endotoxin infusion presented with
reduced extravascular lung water [10,11]. Future studies are
warranted to determine the effects of rhAPC in an ovine
model when the bronchial artery is tied off to clear its
mechanism in ALI.
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